Patients with seborrheic dermatitis intolerant to steroids achieve clearance with Zoryve
Click Here to Manage Email Alerts
Key takeaways:
- Patients with seborrheic dermatitis that cannot use steroids are 3.5 times more likely to achieve clearance with Zoryve vs. vehicle.
- Significantly more patients treated with Zoryve vs. vehicle saw IGA success.
A phase 3 study subgroup analysis showed that patients with seborrheic dermatitis who cannot use topical steroids were more likely to achieve disease clearance with Zoryve topical foam vs. vehicle, Arcutis announced in a press release.
Zoryve foam 0.3% (roflumilast, Arcutis) is a once-daily steroid-free topical for the treatment of adults and adolescents with seborrheic dermatitis. According to data from this analysis, which was presented at the 2024 Winter Clinical Dermatology Conference, patients who were contraindicated, intolerant or unresponsive to steroid topicals were 3.5 times more likely to experience IGA success with Zoryve vs. vehicle (78.8% vs. 48.3%; P < .001).
“This subgroup analysis builds upon the existing evidence for Zoryve foam as an effective once-a-day treatment option for use in all skin and hair types to clear and control seborrheic dermatitis, including among those who previously experienced inadequate response or intolerance to topical steroids,” Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis, said in the release. “As the first topical drug approved with a new mechanism of action for this condition in 20 years, Zoryve foam represents an important advancement in treatment and addresses a truly significant need in this population.”
Additional results found that treatment with Zoryve significantly increased the odds of achieving quality of life improvement vs. vehicle according to the Dermatology Life Quality Index (OR = 6.97; 95% CI, 3.97-12.24).
After 2 weeks of treatment with Zoryve, 72.5% of individuals achieved a minimally important difference in their quality-of-life scores vs. 28.1% treated with vehicle (P = .001). At week 8, this percentage increased to 86.6% among Zoryve-treated patients and 53.6% among vehicle-treated patients (P = .001).
Zoryve was well tolerated and maintained a favorable safety profile with no serious adverse events reported.
Read more about
Click Here to Manage Email Alerts